Moxifloxacin is used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. A meal shortens the QT interval and in some instances it is desirable to use moxifloxacin after a meal which may affect PK or PD or both; however there is no published data.Based on a recent peer-reviewed paper published in January 2014 in the British Journal of Clinical Pharmacology Richmond Pharmacology will present its latest findings as an encore poster presentation at the 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT), taking place 18th to 22nd March, in Atlanta, Georgia.Join Richmond Pharmacology's Dr Jorg Taubel on 21st March between 11h45 and 13h15 (poster number EII-001) for insight into this new area of research.

Latest news

Red4Research Blog – Alan’s Story

June 24, 2025
#Red4Research is a global initiative that recognises the essential role of clinical research in improving treatment, outcomes, and the future of medicine.
Read more

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Events

BioJapan 2025

8th –10th October 2025
Richmond Pharmacology will attend BioJapan 2025 in Yokohama, represented by their leadership team. The event focuses on early-phase trials, UK–Japan collaboration, regulatory strategy, bridging studies, and adaptive trial models.
View event